	US 12,257,270 B2
	Treatment of immune disorders
Silviu Itescu, Melbourne (AU); and Paul Simmons, Melbourne (AU)
Assigned to MESOBLAST INTERNATIONAL SARL, Meyrin (CH)
Filed by Mesoblast International Sarl, Meyrin (CH)
Filed on Jul. 22, 2022, as Appl. No. 17/870,936.
Application 16/828,121 is a division of application No. 15/317,673, granted, now 10,624,930, issued on Apr. 21, 2020, previously published as PCT/EP2015/062138, filed on Jun. 1, 2015.
Application 17/870,936 is a continuation of application No. 16/828,121, filed on Mar. 24, 2020, granted, now 11,406,669.
Claims priority of application No. 2014902194 (AU), filed on Jun. 10, 2014; and application No. 2014902257 (AU), filed on Jun. 13, 2014.
Prior Publication US 2023/0141347 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61K 35/545 (2015.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61P 3/10 (2006.01); A61P 29/00 (2006.01)

CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61K 35/545 (2013.01); A61K 38/17 (2013.01); A61K 38/18 (2013.01); A61P 3/10 (2018.01); A61P 29/00 (2018.01)]

10 Claims

1. A method of treating an inflammatory disease in a subject, the method comprising administering to the subject a composition comprising genetically unmodified stem cells wherein said genetically unmodified stem cells express angiopoietin 1 (Ang1) and vascular endothelial growth factor (VEGF), wherein the VEGF is expressed in an amount from 0.01 μg/10⁶cells to 0.05 μg/10⁶cells.